Company Filing History:
Years Active: 2025
Title: Christoph Thiel: Innovator in Antibody Research
Introduction
Christoph Thiel is a notable inventor based in Cologne, Germany. He has made significant contributions to the field of antibody research, particularly in the development of innovative therapeutic solutions. His work focuses on the interaction of antibodies with human proteins, which has important implications for medical treatments.
Latest Patents
Thiel holds a patent for "Anti-A2AP antibodies and uses thereof." This invention relates to an isolated antibody or antigen-binding fragment that binds to human A2AP. The isolated antibody or fragment has several key characteristics: it cross-reacts with rabbit and/or cynomolgus A2AP, does not inhibit human plasmin activity, and increases plasmin-mediated clot lysis in the presence of A2AP. This patent represents a significant advancement in the understanding and application of antibodies in therapeutic contexts.
Career Highlights
Christoph Thiel is currently employed at Bayer Aktiengesellschaft, a leading global pharmaceutical and life sciences company. His role at Bayer allows him to collaborate with other experts in the field and contribute to groundbreaking research and development projects.
Collaborations
Thiel has worked alongside talented colleagues, including Stefan Heitmeier and Julia Glunz. Their combined expertise fosters an environment of innovation and progress in antibody research.
Conclusion
Christoph Thiel's work in the field of antibody research exemplifies the impact of innovative thinking in medicine. His patent on Anti-A2AP antibodies showcases his commitment to advancing therapeutic solutions. Through his career at Bayer and collaborations with esteemed colleagues, Thiel continues to contribute to significant advancements in healthcare.